WOBURN, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- $Comera Life Sciences (CMRA.US)$, a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced a significant expansion of its SQore patent portfolio with the issuance of four new patents and two new notices of allowance. The six new patents, three issued in the United States and three covering Canada, Korea and India expand the number of proprietary viscosity reducing excipients in Comera's SQore platform and significantly broaden claims covered by previously issued patents.
"We have expanded and strengthened our robust global patent portfolio this year, and these new patents underscore our commitment to innovation and enhance our partnership and pipeline strategy," said Jeffrey Hackman, Chairman and Chief Executive Officer of Comera. "This accomplishment reiterates our position as the trusted partner for developing subcutaneous product formulations which have the potential to improve patient access and ease of use for important biologics. With more than 20 patents and significant continued activity around our partnerships and pipeline, we believe Comera is strongly positioned to transform the delivery of injectable biologics."
Comera is using its proprietary formulation platform, SQore, to enable subcutaneous (SQ) delivery of intravenous (IV) drugs such as monoclonal antibodies (mAbs). The addition of excipients, such as caffeine, interrupts intermolecular interactions to reduce viscosity of high concentration mAb formulations.
The new issuances and allowed patents broaden the number of SQore excipients covered for viscosity reduction claims, including exclusive rights to certain formulations containing combinations of its proprietary excipients. Additionally, the new patents significantly expand previously issued patent claims to provide exclusive rights on magnitude of viscosity reduction versus control, concentration of protein and quantity of excipient in formulations. Today's announcement also marks the first issued patent in India, validating Comera's efforts to ensure a broad geographic scope for SQore patent protection.
About Comera Life Sciences
Leading a compassionate new era in medicine, Comera Life Sciences is applying a deep knowledge of formulation science and technology to transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms. The goal of this approach is to provide patients with the freedom of self-injectable care, reduce institutional dependency and to put patients at the center of their treatment regimen.
馬薩諸塞州沃本，2023年8月8日（GLOBE NEWSWIRE）——開發新一代生物藥物以改善患者獲得機會、安全和便利性的生命科學公司$Comera Life Sciences (CMRA.US)$今天宣佈大幅擴大其Sqore專利組合，發佈四項新專利和兩份新的許可通知。這六項新專利，其中三項在美國頒發，三項涵蓋加拿大、韓國和印度，擴大了ComeraSqore平台中專有降粘劑的數量，並大大擴大了先前頒發的專利所涵蓋的範圍。
Comera董事長兼首席執行官傑弗裏·哈克曼說：“今年，我們擴大並加強了我們強大的全球專利組合，這些新專利凸顯了我們對創新的承諾，並加強了我們的合作伙伴關係和渠道戰略。”“這一成就重申了我們在開發皮下產品配方方面值得信賴的合作伙伴的地位，這些配方有可能改善患者獲得的重要生物製劑的機會和易用性。憑藉20多項專利，圍繞我們的合作伙伴關係和產品線開展大量持續活動，我們相信Comera在改變可注射生物製劑的交付方面處於有利地位。”
Comera正在使用其專有的配方平台SQore來實現單克隆抗體（mAB）等靜脈注射（IV）藥物的皮下（SQ）輸送。添加賦形劑，例如咖啡因，會中斷分子間的相互作用，從而降低高濃度單克隆抗體製劑的粘度。
新發行的專利和允許的專利擴大了降粘度索賠所涵蓋的Sqore賦形劑的數量，包括對某些含有其專有賦形劑組合的配方的專有權。此外，新專利極大地擴大了先前發佈的專利主張，爲配方中粘度降低幅度與控制幅度、蛋白質濃度和賦形劑數量提供了專有權。今天的宣佈也標誌着印度頒發的第一項專利，證實了Comera爲確保Sqore專利保護的廣泛地理範圍所做的努力。
關於 Comera 生命科學
Comera Life Sciences引領着一個富有同情心的醫學新時代，正在應用深厚的配方科學和技術知識，將基本生物藥物從靜脈注射（IV）轉變爲皮下（SQ）形式。這種方法的目標是爲患者提供自由的自我注射護理，減少機構依賴，並將患者置於治療方案的中心。
